PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

Preclinical data suggest that PIK3CA mutations predict response to PI3K/AKT/mTOR inhibitors. Concomitant KRAS or BRAF mutations may mediate resistance. Therefore, tumors from patients referred to the phase I program for targeted therapy starting in October 2008 were analyzed for PIK3CA mutations usi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2011-03, Vol.10 (3), p.558-565
Hauptverfasser:	Janku, Filip, Tsimberidou, Apostolia M, Garrido-Laguna, Ignacio, Wang, Xuemei, Luthra, Rajyalakshmi, Hong, David S, Naing, Aung, Falchook, Gerald S, Moroney, John W, Piha-Paul, Sarina A, Wheler, Jennifer J, Moulder, Stacy L, Fu, Siqing, Kurzrock, Razelle
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Class I Phosphatidylinositol 3-Kinases Female Humans Male Middle Aged Mutation Neoplasms - drug therapy Neoplasms - genetics Neoplasms - metabolism Phosphatidylinositol 3-Kinases - genetics Phosphoinositide-3 Kinase Inhibitors Polymerase Chain Reaction Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins c-akt - antagonists & inhibitors Proto-Oncogene Proteins p21(ras) ras Proteins - genetics TOR Serine-Threonine Kinases - antagonists & inhibitors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!